Vink Patrick V.J.J. Buys Shares in Spero Therapeutics
Vink Patrick V.J.J. purchased 10,000 shares of Spero Therapeutics on June 23, 2026.
Key Points
- Vink Patrick V.J.J. bought 10,000 shares of Spero Therapeutics, Inc. (SPRO) on June 23, 2026.
- Spero Therapeutics shares traded near $2.02 on Friday, with a market cap of approximately $116.96 million.
- Analyst firm HC Wainwright & Co. reiterated a buy rating with a $5.00 price target on January 30, 2025.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 23, 2026, Vink Patrick V.J.J. purchased 10,000 shares of Spero Therapeutics, Inc. (NasdaqGS: SPRO). This insider transaction did not involve a planned purchase, and no specific price or total value was disclosed. Shares traded near $2.02 on Friday.
Insider Buying and Selling at Spero Therapeutics, Inc.
Vink Patrick V.J.J. was not the only insider buying shares of Spero Therapeutics on June 23, 2026. Scott Thomas Jackson, John Jr. Pottage, Milind Deshpande, Cynthia Smith, and Frank Thomas each purchased 20,000 shares. These transactions were also not part of any pre-planned trading programs.
Spero Therapeutics, Inc. Stock Up 68.3%
Shares of NasdaqGS:SPRO traded near $2.02 on Friday. Spero Therapeutics, Inc. has a market cap of about $116.96 million, with a P/E ratio of 7.48. The stock's 52-week range is between $1.80 and $3.22, and it has a 50-day moving average of $2.63 and a 200-day moving average of $2.40. The company's beta is 1.456, indicating some volatility compared to the market.
$SPRO stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On January 30, 2025, HC Wainwright & Co. reiterated its buy rating for Spero Therapeutics with a price target of $5.00. The stock has a consensus recommendation of 'hold' based on one analyst opinion, with a mean target price of $4.00.
About Spero Therapeutics
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Cambridge, Massachusetts. It focuses on developing treatments for multi-drug resistant bacterial infections and rare diseases. The company is advancing product candidates like Tebipenem HBr, an oral antibiotic targeting complicated urinary tract infections. Spero collaborates with Meiji Seika Pharma Co., Ltd. and Everest Medicines to develop and commercialize its treatments in various regions.
Bottom Line
Insider buying activity, like Vink Patrick V.J.J.'s purchase, often attracts attention from investors who track potential signals of confidence from company insiders. It's important to remember that these transactions are reported after they occur and may not reflect current positions. Spero Therapeutics continues to be a focus in the biotech sector, especially with its efforts in addressing multi-drug resistant infections.
Get Spero Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SPRO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.